Abstract 356P
Background
Although major part of PC is diagnosticated in elderly, PC pts older than 70 years old are poorly represented in randomized clinical trials (RCT); therefore, limited efficacy and safety data are available. This study wants to evaluate the clinicopathological characteristics of advanced LOPC and the effectiveness of systemic treatment.
Methods
Real-world data were collected by the Gemelli GENERATOR facility within the Gemelli Science and Technology Park (G-STeP). Study population was identified from record of pts treated at our Institution from Jan-2018 to Jun-2023 matching three inclusion criteria: pts hospitalized with a diagnosis of PC (International Classification of Disease 9 (ICD-9) codes captured from structured data source), pts with a pathology report including PC evidence and pts with an hospital discharge letter including PC evidence (selected using clinically validated text mining techniques from unstructured data source). Clinicopathological variables of LOPC pts were extracted using SAS (SAS(R) Institute suite for ETL); statistical analyses were conducted using R software.
Results
A total of 915 pts treated at our Institution were included; of those, 210 (23%) had locally advanced or metastatic pancreatic cancer and were older than 70 years old (LOPC). Median age was 76.1 (75.6-79.9), 53% were female, the median BMI was 23.4 (95% CI 22.7-24). More than half of the population (54%) had at least 2 comorbidities at the time of diagnosis and only 9.3% of the pts had none; the most frequent were blood high blood pressure (55.4%) and diabetes (28.4%). Seventy-five pts (35.7%) had locally advanced PC and 135 pts (64.3%) had de novo metastatic disease. Median overall survival (mOS) was 9.9 months (95% CI 8.1-11.7) and 1st line’s mPFS was 6.5 months (95% CI 5.7-7.3). Both ECOG PS (0-1 vs 2) and chemotherapy’s regimen (FOLFIRINOX vs gemcitabine - nab-paclitaxel vs gemcitabine) were associated with both mOS and mPFS at the univariate analysis, but only ECOG PS remained significant at the multivariate analysis (p<0.001).
Conclusions
Our experience showed that, despite their poor presence in RCT, advanced LOPC pts should be candidate to a first-line treatment in particular when in good general conditions.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.